Olema Pharmaceuticals (OLMA) Cash from Investing Activities (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Cash from Investing Activities for 7 consecutive years, with $4.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 110.05% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at -$106.1 million (up 10.4% YoY), while the FY2025 annual figure was -$155.8 million, down 66.54% from the prior year.
• Cash from Investing Activities advanced to $4.5 million in Q1 2026 per OLMA's latest filing, from -$162.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $45.9 million in Q3 2024 and bottomed at -$162.2 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$9.3 million across 5 years, with a median of $14.1 million in 2023.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities tumbled 289.24% — and 2025, when it jumped 801.8%.
• Olema Pharmaceuticals' Cash from Investing Activities stood at $16.3 million in 2022, then sank by 289.24% to -$30.9 million in 2023, then sank by 270.12% to -$114.4 million in 2024, then plunged by 41.74% to -$162.2 million in 2025, then soared by 102.79% to $4.5 million in 2026.
• Business Quant data shows OLMA's Cash from Investing Activities at $4.5 million in Q1 2026, -$162.2 million in Q4 2025, and $17.3 million in Q3 2025.